DCPH News and Press, Deciphera Pharmaceuticals Inc. From 01/05/21

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 AM ET. A live webcast of the event will be available on...

Commenting on the proposed merger between Alexion (ALXN) and AstraZeneca (AZN), Piper Sandler highlights the ‘durability’ of large biotech businesses, ‘with Astra pointing to double-digit EPS accretion in years 1-3’ from the deal.“If the market doe...

Deciphera Pharmaceuticals (DCPH) has completed the enrollment of ~426 gastrointestinal stromal tumor ((GIST)) patients in a Phase 3 clinical trial, INTRIGUE, evaluating Qinlock (ripretinib) in a second-line setting compared to Pfizer's (PFE) Sutent (sunitinib) .The primary endpoint is progres...

– Top-line Results Expected in Second Half of 2021 – – Study Designed to Evaluate the Efficacy and Safety Profile of QINLOCK Compared to Sunitinib in Patients Previously Treated with Imatinib – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, has participated in a fireside chat in advan...

– Magazine honors the best employers in Massachusetts – Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, has been named one of the ​T...

Deciphera Pharmaceuticals (DCPH) has announced preliminary results from the ongoing Phase 1/2 study evaluating DCC-3014 in patients with tenosynovial giant cell tumor ((TGCT)), a non-malignant cancer of the joint or tendon sheath that results in severe functional limitations. Data will be pre...

– Deciphera Presents the First and Largest Baseline Genomic Analysis by Tumor and Liquid Biopsy in Fourth-line Patients with GIST – – Results from an Exploratory Analysis of the Phase 3 INVICTUS Study in Fourth-line GIST Demonstrate the Broad Clinical Acti...

– Preliminary Results Showed 41% (9 of 22 Patients) Objective Response Rate, Including One Confirmed Complete Response – – Treatment was Generally Well-Tolerated with Treatment-Emergent Adverse Events Mostly Grade 1 or 2 – – Based on ...

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced that Steve Hoerter, President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17 at 9:40 AM ET. A live webcast of the event will be available on the &#...